Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Progressive Corp — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Progressive Corp trades at $215.59 (market cap $129.36B). The key difference: Progressive Corp is far larger — about 133× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Progressive Corp pays a 0.18% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Progressive Corp for 81 Days on average.
| MRVI | PGR | |
|---|---|---|
Market Cap | $972.90M | $129.36B |
Volume | 4,325,710 | 3,501,619 |
Sector | Health | Financials |
52-Week High | $9.00 | $236.18 |
52-Week Low | $2.83 | $190.40 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $1.08B | $137.57B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
PGR trades at $213.46, down 3.1% on the day, amid mixed earnings results with recent Q3 2026 miss. The stock shows strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and net income margin of 12.85%. Technicals are bullish with moving averages supporting upside, while RSI levels indicate potential overbought conditions. Recent news highlights Progressive's telematics edge and inclusion in dividend-focused articles.
Outlook remains positive with analyst consensus target of $222.23 implying ~4% upside. Key opportunities include sustained underwriting strength and dividend reliability, but risks involve competitive pressures in auto insurance and earnings volatility. The stock's valuation at P/E of 11.18 appears reasonable relative to profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
